Orthofuse, a London-based orthopaedic medtech company developing advanced 3D-printed implant systems, has secured £2.2 million in seed funding to accelerate the development and commercialization of its next-generation orthopaedic solutions. The round was led by a group of angel investors, with participation from ACF Investors, Cambridge Angels and Empirical Ventures. The capital will support continued product development, regulatory preparation, and early-stage clinical evaluation as the company advances toward market readiness.
Orthofuse is focused on reengineering implant architecture using additive manufacturing to simplify surgical procedures and improve patient safety. Traditional implant systems can be complex to position and difficult to adjust once deployed, often extending operating times and increasing procedural risk. The company’s technology is designed to better align with real-world surgical workflows, enabling greater intraoperative flexibility and reversibility while maintaining structural integrity.
By leveraging 3D printing, Orthofuse aims to deliver implants that reduce surgical complexity and enhance outcomes in orthopaedic trauma and spinal procedures. The company believes its approach can set a new benchmark for safety, efficiency and usability in orthopaedic care.
KEY QUOTES
“Modern surgical practice demands implant systems that reflect the realities of the operating room. Orthofuse is developing a technology designed to simplify procedures, giving surgeons greater flexibility and confidence. This investment enables us to accelerate progress toward setting a new standard for safety and efficiency in orthopaedic care.”
James Scott, CEO And Co-Founder, Orthofuse
“Orthofuse has reimagined the fundamental architecture of implants to solve the inefficiencies of current solutions. We believe this approach has real value in improving orthopaedic care, and are pleased to support the team as they move forward.”
Didier Cowling, Lead Investor And Board Member
“Orthofuse is tackling a critical challenge in surgery by coupling advanced engineering and clinical practicality. James and his team have developed a truly innovative approach to implant architecture that has the potential to significantly improve patient outcomes whilst enhancing surgical efficiency, and we are delighted to support them in this journey.”
Tim Mills, Managing Partner, ACF Investors
